ASN's Mission

ASN leads the fight to prevent, treat, and cure kidney diseases throughout the world by educating health professionals and scientists, advancing research and innovation, communicating new knowledge, and advocating for the highest quality care for patients.

learn more

Contact ASN

1401 H St, NW, Ste 900, Washington, DC 20005


The Latest on Twitter

Kidney Week

Abstract: FR-PO305

The Association Between Serum Uric Acid Levels and Cardiovascular Disease in Japanese Patients with CKD: The FKR Study

Session Information

Category: CKD (Non-Dialysis)

  • 2101 CKD (Non-Dialysis): Epidemiology, Risk Factors, and Prevention


  • Takae, Keita, Japanese Red Cross Fukuoka Hospital, Fukuoka, Japan
  • Nakai, Kentaro, Japanese Red Cross Fukuoka Hospital, Fukuoka, Japan
  • Tanaka, Shigeru, Kyushu University, Fukuoka, Japan
  • Inoue, Megumi, Japanese Red Cross Fukuoka Hospital, Fukuoka, Japan
  • Kohara, Chiaki, Japanese Red Cross Fukuoka Hospital, Fukuoka, Japan
  • Yamamoto, Shutaro, Japanese Red Cross Fukuoka Hospital, Fukuoka, Japan
  • Mitsuiki, Koji, Japanese Red Cross Fukuoka Hospital, Fukuoka, Japan
  • Nakano, Toshiaki, Kyushu University, Fukuoka, Japan
  • Tsuruya, Kazuhiko, Nara Medical University, Kashihara, Japan
  • Kitazono, Takanari, Kyushu University, Fukuoka, Japan

Growing evidence suggests that high serum uric acid (SUA) level is related to increased risk of cardiovascular disease (CVD). However, limited studies have investigated the influence of elevated SUA level on the prevalence of CVD in Japanese patients with chronic kidney disease (CKD). Besides, the nature of disease in Asian populations differs markedly from that in North American populations and European.


The Fukuoka Kidney disease Registry (FKR) is designed as one of the largest prospective, multicenter, observational cohort studies in non-dialyzed CKD patients. A total of 3,366 Japanese patients with CKD were eligible for this study. The association between SUA level and the prevalence of CVD was analyzed. CVD was defined as ischemic heart disease, hemorrhagic stroke, ischemic stroke, congestive heart failure, atrial fibrillation, and aneurism of thoracic or abdominal artery. The odds ratios (ORs) for the prevalence of CVD were estimated according to SUA levels as follows: ≤5.9 mg/dL, 6.0-7.9 mg/dL, and ≥8.0 mg/dL.


The CVD was present in 857 (25.5%) patients. Mean serum uric acid was 6.2 ± 1.5 (standard deviation) mg/dL. The age- and sex-adjusted prevalence of CVD increased significantly (SUA ≤5.9 mg/dL: 22.9%, 6.0-7.9 mg/dL: 26.1%, and ≥8.0 mg/dL: 33.2%, [p for trend <0.05]). Compared with those with SUA ≤5.9 mg/dL, the multivariable-adjusted ORs for the prevalence of CVD were 1.11 (95% confidence intervals, 0.92-1.35) and 1.38 (1.04-1.84) in those with SUA 6.0-7.9 mg/dL and ≥8.0 mg/dL, respectively. Among CVD subtypes, higher SUA levels were associated with increased prevalence of atrial fibrillation (ORs [95% CI]: 1.38 [0.97-1.98] and 2.41 [1.50-3.89], respectively).


Higher SUA levels are associated with higher prevalence of CVD, especially with atrial fibrillation. The FKR study will prospectively clarify whether higher SUA levels increase risk for developing CVD in Japanese patients with CKD.